Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59142 | 1.00 | — | — | |
| Water SCHEMBL16115412 | 1.00 | — | — | |
| SCHEMBL28797694 | 1.00 | — | — | |
| Water SCHEMBL10918338 | 1.00 | LOX (0.50) | — | |
| Hydrochloric Acid SCHEMBL116850 | 0.95 | — | — | |
| SCHEMBL29659381 | 0.95 | — | — | |
| Bromide SCHEMBL21357333 | 0.95 | — | — | |
| Hydrogen Sulfide SCHEMBL28088172 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL27915489 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL6183079 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106166480-B | Adsorbent material and its preparation method and application a kind of while that there is cation exchange and reverse phase reserve capability | 浙江省中医药研究院 | 2019-06-25 | — | — | CN | claimed |
| WO-2024107859-A1 | CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230372360-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING ABERRANT INFLAMMATION IN PERI-OCULAR SECRETORY GLANDS OR AT THE OCULAR SURFACE | CS PHARMACEUTICALS LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11759472-B2 | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface | CS PHARMACEUTICALS LIMITED (GB) | 2023-09-19 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| US-11197867-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210377495-A1 | AMINOPYRIMIDINYL COMPOUNDS | PFIZER INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-11168249-B1 | Luminescent polydentate polycyclic compounds for metal ions | ZAVALETA FERNANDEZ DE CORDOVA ANDRES (US) | 2021-11-09 | — | — | US | disclosed |
| US-10980815-B2 | Aminopyrimidinyl compounds | PFIZER INC. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-0288423-A1 | Process for the preparation of substituted sulfonamidobenzamides and a novel intermediate thereto | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-10-26 | — | — | EP | disclosed |
| EP-0158775-B1 | SUBSTITUTED SULFONAMIDOBENZAMIDES, ANTIARRYTHMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-20 | — | — | EP | disclosed |
| US-4689341-A | Antiarrhythmic imidazoles | SCHERING A.G. (DE) | 1987-08-25 | — | — | US | disclosed |
| US-4629739-A | Substituted sulfonamidobenzamides and method of treating arrhythmias | SCHERING A.G. (DE) | 1986-12-16 | — | — | US | disclosed |
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | disclosed |
| US-4599344-A | Quinuclidines and quinuclidinium salts as antiarrhythmic agents | SCHERING A.G. (DE) | 1986-07-08 | — | — | US | disclosed |
| US-4581370-A | Antiarrhythmic imidazoliums | SCHERING A.G. (DE) | 1986-04-08 | — | — | US | disclosed |
| EP-0158775-A1 | Substituted sulfonamidobenzamides, antiarrythmic agents and compositions thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | disclosed |
| US-4544654-A | Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof | SCHERING A.G. (DE) | 1985-10-01 | — | — | US | disclosed |
| EP-0098951-A2 | Aminobenzamide derivatives and preparation thereof | STERLING DRUG INC. (US) | 1984-01-25 | — | — | EP | disclosed |